Leading investors with more than $15 trillion of assets under management participated in the meeting. RDIF presented 25 pharmaceutical companies that have partnered with the Fund for production
February 15, 2021 • 10:17 am CST (Precision Vaccinations)
The Karaganda Pharmaceutical Complex, located in Karaganda, Kazakhstan, announced on February 15, 2021, plans to leverage the Sputnik V vaccine to produce the QazCovid-In Vaccine, reported TASS.
This COVID-19 vaccine candidate is currently undergoing a phase 3 clinical study sponsored by Research Institute for Biological Safety Problems. This study s estimated Primary Completion Date is March 31, 2021.
On February 1st, Kazakhstan began its coronavirus vaccination campaign by administering the Sputnik V vaccine, which is authorized in about 26 countries.
The COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.